Trends in Cardiovascular Medicine
Volume 15, Issue 6 , Pages 207-211 , August 2005

Tiny Solutions for Giant Cardiac Problems

  • David F. Kong

      Affiliations

    • Corresponding Author InformationAddress correspondence to: David F. Kong, MD, Duke Clinical Research Institute, Duke University Medical Center, Box 3850, Durham, NC 27710, USA. Tel.: (+1) 919-668-8946; fax: (+1) 919-668-7056.
    • ,
  • Pascal J. Goldschmidt-Clermont

References 

  1. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583–591
  2. Barr E, Leiden JM. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science. 1991;254:1507–1509
  3. Baughman RH, Zakhidov AA, de Heer WA. Carbon nanotubes—the route toward applications. Science. 2002;297:787–792
  4. Bittl JA. Medical progress: advances in coronary angioplasty. N Engl J Med. 1996;335:1290–1302
  5. Bulte JWM, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 2001;19:1141–1147
  6. Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J. 1999;138:S1–S5
  7. Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325–338
  8. Culver K, Cornetta K, Morgan R, et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci USA. 1991;88:3155–3159
  9. Drexler KE. Engines of creation: the coming era of nanotechnology. New York, NY: Bantam Doubleday Dell; 1986;
  10. Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature. 1988;331:35–41
  11. Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol. 2003;41:70S–78S
  12. Falotico R, Kopia GA, Llanos GH, et al. Antiinflammatory drug and delivery device. Cordis Corporation; 2004;850232(6776796)
  13. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 2001;89:305–316
  14. Flowers ME, Stockschlaeder MA, Schuening FG, et al. Long-term transplantation of canine keratinocytes made resistant to G418 through retrovirus-mediated gene transfer. Proc Natl Acad Sci USA. 1990;87:2349–2353
  15. Kaji EH, Leiden JM. Gene and stem cell therapies. JAMA. 2001;285:545–550
  16. Kelly BD, Hackett SF, Hirota K, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 2003;93:1074–1081
  17. Knight DM, Wagner C, Jordan R, et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol. 1995;32:1271–1281
  18. Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation. 2003;108:3134–3139
  19. Kong DF. Steroids for restenosis: strike three!. Am Heart J. 1999;138:3–4
  20. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829–2835
  21. Llevadot J, Giugliano RP. New thrombolytic agents: does direct angioplasty still have a role?. Curr Interv Cardiol Rep. 2000;2:250–257
  22. Palmer TD, Thompson AR, Miller AD. Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood. 1989;73:438–445
  23. Ponder KP, Gupta S, Leland F, et al. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci USA. 1991;88:1217–1221
  24. Potapova I, Plotnikov A, Lu Z, et al. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res. 2004;94:952–959
  25. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117–1124
  26. Simpson ML. Rewiring the cell: synthetic biology moves towards higher functional complexity. Trends Biotechnol. 2004;22:555–557
  27. U.S. Food and Drug Administration. Taxus Express Coronary Stent System (P030025): Summary of safety and effectiveness data. 2004;
  28. Van Den Bos EJ, Wagner A, Mahrholdt H, et al. Improved efficacy of stem cell labeling for magnetic resonance imaging studies by the use of cationic liposomes. Cell Transplant. 2003;12:743–756
  29. Verstraete M. Third-generation thrombolytic drugs. Am J Med. 2000;109:52–58
  30. World Health Organization. Atlas of heart disease and stroke. Geneva, Switzerland: World Health Organization; 2004;
  31. Yang D, Stanslaski JL, Wang L, et al. Stent coating. SciMed Life Systems, Inc.; 2004;346975(6258121)

PII: S1050-1738(05)00122-2

doi: 10.1016/j.tcm.2005.07.003

Trends in Cardiovascular Medicine
Volume 15, Issue 6 , Pages 207-211 , August 2005

Article Tools

* Image Usage & Resolution